KLF9 and autoimmune thrombocytopenic purpura: In immune thrombocytopenia (ITP) patients treated with TPO receptor agonists (TPO-RAs), KLF9 downregulation in MDSCs enhanced immunosuppressive functions by upregulating GADD34 expression.